Imugene (ASX:IMU) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application number that protects its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR-T cell therapies.

CLINUVEL (ASX:CUV) has announced final results from its Phase 2 pilot study evaluating SCENESSE (afamelanotide) as a monotherapy in patients with the depigmentation disorder vitiligo.

Scientists working at RMIT University and Osaka University have discovered that the internal shape of tiny drug-delivery particles, known as lipid nanoparticles, has a significant impact on how well our cells absorb them.

The US FDA has approved an Investigational New Drug, enabling the Melbourne-based company Myrio to progress its lead product into human clinical trials.

Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has entered into a commercial manufacturing agreement with SpectronRx for the company's lead diagnostic product, 64Cu-SAR-bisPSMA.

Amplia Therapeutics (ASX:ATX) has announced important new data from its ongoing ACCENT clinical trial in pancreatic cancer.

James Graham, CEO of Recce Pharmaceuticals, said, “This facility marks a significant step in strengthening our capital position at a critical juncture."

The global initiative aims to engage governments, institutions, enterprises, and organisations in submitting innovative proposals that integrate Taiwan’s home-grown health innovations.

Cochlear has launched its new smart cochlear implant system, Cochlear Nucleus Nexa System, which is designed and manufactured in Australia.

Radium Capital, Australia’s leader in R&D finance, has announced plans to lend $400 million to Australian innovators over the next 12 months. 

Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA) has provided top-line results from its Phase 2a/b PROTECT Trial of ISLA101 in a human challenge model of dengue virus infection.

Cyclopharm (ASX:CYC) has announced that the United States Patent and Trademark Office (USPTO) has granted the maximum allowable patent term extension of five years covering the TECHNEGAS Kit (technetium Tc-99m labelled carbon) to 2031.

AusBiotech 2025, Australia’s premier life sciences and investment conference, has officially opened early bird registrations, and the countdown is on.

In its once-in-a-decade report ‘Our Future World’, Australia’s national science agency identified seven global megatrends that will shape our lives in the coming decades. Among them is the escalating health imperative.

New data presented today at the Public Health Association of Australia's Communicable Diseases and Immunisation Conference have shown that cell-based influenza vaccines were nearly 20 per cent more effective at preventing test-confirmed infections compared to traditional standard-dose egg-based vaccines.

Syntara (ASX:SNT) has announced that its lead candidate, SNT5505, has been granted Fast Track Designation by the US FDA for the treatment of myelofibrosis in patients with an inadequate response to JAK inhibitor therapy.

Argenica Therapeutics (ASX:AGN) states that it has received correspondence from the US FDA, indicating that a clinical hold has been placed on the company's Investigational New Drug Application.